Quick Takeaways
- Mark J. Enyedy has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,160,029.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Mark J. Enyedy
- Location
- San Diego, CA
- Summary
- The estimated net worth of Mark J. Enyedy is at least $2,160,029 dollars as of 04 Jun 2025. Mark J. Enyedy is the CHIEF EXECUTIVE OFFICER, Director of ImmunoGen, Inc. and owns shares of ImmunoGen, Inc. stock worth about $897.8K. Mark J. Enyedy is the Director of BIOMARIN PHARMACEUTICAL INC and owns shares of BIOMARIN PHARMACEUTICAL INC (BMRN) stock worth about $853.4K. Mark J. Enyedy is the Director of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and owns shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) stock worth about $408.9K.
- Signature
- /s/ Mark Enyedy
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mark J. Enyedy and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: ImmunoGen, Inc. ($897,750).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Mark J. Enyedy
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| IMGN | ImmunoGen, Inc. | CHIEF EXECUTIVE OFFICER, Director | $897,750 | 12 Feb 2024 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | Director | $853,379 | 20 May 2025 | ||
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Director | $408,900 | 02 Jun 2025 | ||
| LOGC | LogicBio Therapeutics, Inc. | Director | 16 Nov 2022 |
Insider Transactions Reported by Mark J. Enyedy:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.